TY - JOUR AU - Earl, H M; Hiller, L; Vallier, A L TI - PERSEPHONE Steering Committee and Trial Investigators. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial JO - Lancet VL - 393 PY - 2019 DO - 10.1016/S0140-6736(19)30650-6 L3 - PubMed-ID: 31178152 SP - 2599 EP - 2612 N1 - (10191) ER -